NYU Langone Health Apr 3 2025 A study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP inhibitors. Recently published in Nature , the work builds on the fact that as human cells divide and grow, DNA damage occurs continuously and must be swiftly repaired to prevent cancer. BRCA2 is a key player in this mechanism—homology-directed repair—but genetic changes, called

Tag-uri: DNA